Cara Therapeutics | CARA - Operating Profit


Cara Therapeutics reported $-7.05M in Operating Profit for its fiscal quarter ending in March of 2026.





Operating Profit Change Date
Acadia Pharmaceuticals USD 71.72M 33.88M Sep/2026
Alterity Therapeutics Limited AUD -8.07M 302.4K Dec/2025
Cara Therapeutics USD -7.05M 1.11M Mar/2026
Cassava Sciences USD -9.39M 1.78M Jun/2026
Chugai Pharma JPY 202.95B 42.09B Sep/2026
Cipla INR 10.43B 1.55B Sep/2026
Clal Biotechnology ILS -1.74M 7.46M Dec/2022
Compugen USD -8.84M 180K Jun/2026
CSL USD 2.64B 1.97B Dec/2025
Grifols EUR 320.55M 91.01M Dec/2025
Halozyme Therapeutics USD -60.68M 3.04M Sep/2026
J&J USD 6.47B 1B Sep/2026
Neurocrine Biosciences USD 343M 123.1M Sep/2026
Pacira USD 2.57B 2.56B Sep/2026
Pfizer USD 662M 5M Sep/2026
RedHill Biopharma USD -4.22M 1.8M Jun/2024
Supernus Pharmaceuticals USD -21.04M 14.21M Jun/2026
Vanda Pharmaceuticals USD -40.66M 29.66M Dec/2024